HAMI 3379

HAMI 3379 is a potent and selective CysLT2 receptor antagonist. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation[1][2].

Product Specifications

CAS Number

[1245653-57-9]

UNSPSC

12352005

Target

Leukotriene Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/hami-3379-1.html

Concentration

10mM

Purity

98.64

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)C1=CC=C(OCCCC2=CC=C(OCCCCOC3CCCCC3)C=C2)C(C(N[C@@H]4C[C@@H](C(O)=O)CCC4)=O)=C1

Molecular Formula

C34H45NO8

Molecular Weight

595.72

References & Citations

[1]F Wunder, et al. Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT (2) ) receptor. Br J Pharmacol. 2010 May;160 (2) :399-409.|[2]Q J Shi, et al. HAMI 3379, a CysLT2R antagonist, dose- and time-dependently attenuates brain injury and inhibits microglial inflammation after focal cerebral ischemia in rats. Neuroscience. 2015 Apr 16;291:53-69.